Key result
Peritoneal dialysate infusion fails to alter corrected QT dispersion or cardiac injury markers in CAPD.
Why the study?
The acute cardiac effect of increased abdominal pressure due to infused dialysate during continuous ambulatory peritoneal dialysis (CAPD) was not clear.
Does infusion of peritoneal dialysate fluid alter QT dispersion and cardiac injury markers in patients with continuous ambulatory peritoneal dialysis?
Observational (n=30)
Does infusion of peritoneal dialysate fluid alter QT dispersion and cardiac injury markers in patients with continuous ambulatory peritoneal dialysis?
Acute infusion of peritoneal dialysate fluid does not significantly alter QT dispersion or cardiac injury markers in patients on continuous ambulatory peritoneal dialysis.
No acute QTd or biomarker change with dialysate infusion in CAPD; leaves open long-term volume effects on arrhythmia risk.
AIM: The leading cause of mortality in dialysis patients is cardiovascular complications, including ventricular arrhythmias and sudden cardiac death. QT dispersion (QTd), a simple noninvasive arrhythmogenic marker, is used to assess homogeneity of cardiac repolarization. It was also significantly prolonged in continuous ambulatory peritoneal dialysis (CAPD) patients. The acute cardiac effect of increased abdominal pressure due to infused dialysate during CAPD is not clear yet. In this study we aimed to evaluate corrected QTd (cQTd) and cardiac injury markers such as plasma pro-brain natriuretic peptide (proBNP) and troponin I (TnI) in CAPD patients before and after an infusion of peritoneal dialysate fluid. METHODS: Thirty subjects (16 women, 14 men; mean age, 40.21 ± 12.34 years) enrolled in our study. QTd, cQTd, maximum QT (QTmax), maximum corrected QT (cQTmax), minimum QT (QTmin), and minimum corrected QT (cQTmin) intervals were measured from standard 12-lead electrocardiography. RESULTS: We found that cQTmax, cQTmin, and cQTd were not changed from baseline measurement after infusion of dialysate in CAPD patients (460 ± 49 vs. 460 ± 38, p = 0.9; 410 ± 36 vs. 410 ± 41, p = 0.8; 470 ± 30 vs. 460 ± 25, p = 0.7, respectively). There were no statistically significant differences between before and after peritoneal dialysate according to the levels of proBNP and TnI (155.64 ± 76.41 vs. 208.30 ± 118.46, p = 0.2; 0.008 ± 0.007 vs. 0.01 ± 0.011; p = 0.4, respectively). CONCLUSION: In conclusion, we did not find any significant effect of peritoneal dialysate fluid infusion volume on QTd and cardiac injury markers in patients with chronic renal failure receiving CAPD therapy, which is thought to be a safer modality of dialysis.
No takes yet. Share an insight, caveat, or question.
Koçak et al. (2011) conducted an observational in Continuous ambulatory peritoneal dialysis (CAPD) (n=30). Infusion of peritoneal dialysate fluid vs. Baseline (before infusion) was evaluated on Corrected QT dispersion (cQTd) (p=0.7). Infusion of peritoneal dialysate fluid did not significantly alter corrected QT dispersion (470 vs 460, p=0.7) or cardiac injury markers in patients receiving continuous ambulatory peritoneal dialysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: